5 June 2017 – cancer study success
The company has announced that researchers have presented successful results from their work using ANGLE’s Parsortix system in tests on colorectal cancer undertaken at The University of Texas MD Anderson Cancer Centre. The results of the study add to the body of evidence driving adoption of Parsortix in the fast growing liquid biopsy market. This is clearly further good news and although the shares have ticked up on the news they remain a LONG TERM BUY.